Wall Street brokerages expect that Urovant Sciences Ltd (NASDAQ:UROV) will post earnings of ($0.92) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Urovant Sciences’ earnings. The lowest EPS estimate is ($1.00) and the highest is ($0.80). The company is scheduled to issue its next quarterly earnings results on Thursday, September 12th.
According to Zacks, analysts expect that Urovant Sciences will report full-year earnings of ($4.14) per share for the current fiscal year, with EPS estimates ranging from ($4.84) to ($3.63). For the next financial year, analysts anticipate that the company will report earnings of ($3.55) per share, with EPS estimates ranging from ($4.69) to ($2.34). Zacks’ EPS calculations are an average based on a survey of research firms that cover Urovant Sciences.
Urovant Sciences (NASDAQ:UROV) last released its quarterly earnings data on Thursday, June 13th. The company reported ($0.96) EPS for the quarter, hitting analysts’ consensus estimates of ($0.96).
A number of equities analysts have commented on the stock. SunTrust Banks lifted their price objective on shares of Broadcom to $339.00 and gave the stock a “buy” rating in a report on Friday, March 15th. They noted that the move was a valuation call. HC Wainwright set a $126.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a report on Monday, June 24th. JPMorgan Chase & Co. set a $24.00 price objective on shares of Urovant Sciences and gave the stock a “buy” rating in a report on Friday, June 14th. Finally, Zacks Investment Research downgraded shares of Horiba from a “hold” rating to a “sell” rating in a report on Wednesday, May 22nd. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $21.63.
Urovant Sciences stock traded down $0.13 during mid-day trading on Friday, reaching $9.24. The company’s stock had a trading volume of 273 shares, compared to its average volume of 73,525. The company has a market capitalization of $280.56 million and a price-to-earnings ratio of -2.14. The firm’s 50 day moving average is $7.94. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 0.18. Urovant Sciences has a twelve month low of $4.05 and a twelve month high of $14.49.
In other news, major shareholder Holdings Ltd. Dexxon purchased 11,608 shares of Urovant Sciences stock in a transaction dated Friday, May 17th. The stock was bought at an average price of $7.10 per share, with a total value of $82,416.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Andrew Lo purchased 19,830 shares of Urovant Sciences stock in a transaction dated Thursday, May 23rd. The shares were purchased at an average cost of $8.22 per share, with a total value of $163,002.60. The disclosure for this purchase can be found here. In the last three months, insiders have bought 167,952 shares of company stock valued at $1,330,019.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Weiss Multi Strategy Advisers LLC boosted its holdings in shares of Urovant Sciences by 38.2% during the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock valued at $99,000 after acquiring an additional 4,146 shares during the period. Marshall Wace North America L.P. acquired a new stake in Urovant Sciences in the first quarter worth about $49,000. Barclays PLC acquired a new stake in Urovant Sciences in the fourth quarter worth about $37,000. Two Sigma Investments LP acquired a new stake in Urovant Sciences in the fourth quarter worth about $72,000. Finally, Marshall Wace LLP acquired a new stake in Urovant Sciences in the first quarter worth about $325,000. 21.92% of the stock is owned by institutional investors.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Recommended Story: What is an investor looking for in an SEC filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.